Ying‐Hao Shen

2.3k total citations · 1 hit paper
75 papers, 1.5k citations indexed

About

Ying‐Hao Shen is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Ying‐Hao Shen has authored 75 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hepatology, 26 papers in Oncology and 21 papers in Epidemiology. Recurrent topics in Ying‐Hao Shen's work include Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Liver Disease Diagnosis and Treatment (15 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers). Ying‐Hao Shen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Liver Disease Diagnosis and Treatment (15 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers). Ying‐Hao Shen collaborates with scholars based in China, Ethiopia and United States. Ying‐Hao Shen's co-authors include Jia Fan, Hui‐Chuan Sun, Jian Zhou, Xiao‐Dong Zhu, Cheng Huang, Ying‐Hong Shi, Yuan‐Fei Peng, Zhen‐Bin Ding, Ai‐Wu Ke and Yuan Ji and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Ying‐Hao Shen

67 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

2021 159 citations Xiao‐Dong Zhu, Cheng Huang et al. Liver Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ying‐Hao Shen China	23	571	499	447	418	413	75	1.5k
Jeong Eun Yoo South Korea	24	682 1.2×	682 1.4×	454 1.0×	418 1.0×	480 1.2×	48	1.8k
Johann von Felden Germany	19	679 1.2×	769 1.5×	493 1.1×	658 1.6×	456 1.1×	44	1.9k
Stefano Caruso France	28	969 1.7×	391 0.8×	292 0.7×	687 1.6×	471 1.1×	55	1.9k
Stefania Brozzetti Italy	21	586 1.0×	337 0.7×	343 0.8×	393 0.9×	468 1.1×	50	1.6k
Tong‐Chun Xue China	22	466 0.8×	405 0.8×	208 0.5×	321 0.8×	501 1.2×	41	1.3k
Weijia Liao China	21	663 1.2×	328 0.7×	231 0.5×	445 1.1×	360 0.9×	64	1.3k
Xiaoying Wang China	13	489 0.9×	332 0.7×	267 0.6×	276 0.7×	460 1.1×	52	1.3k
Sandrine Boyault France	14	1.0k 1.8×	503 1.0×	298 0.7×	503 1.2×	351 0.8×	20	1.7k
Miguel Albuquerque France	19	333 0.6×	486 1.0×	420 0.9×	258 0.6×	238 0.6×	39	1.2k
Ao Huang China	21	725 1.3×	572 1.1×	265 0.6×	787 1.9×	574 1.4×	51	1.9k

Countries citing papers authored by Ying‐Hao Shen

Since Specialization

Citations

This map shows the geographic impact of Ying‐Hao Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying‐Hao Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying‐Hao Shen more than expected).

Fields of papers citing papers by Ying‐Hao Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying‐Hao Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying‐Hao Shen. The network helps show where Ying‐Hao Shen may publish in the future.

Co-authorship network of co-authors of Ying‐Hao Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Ying‐Hao Shen. A scholar is included among the top collaborators of Ying‐Hao Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying‐Hao Shen. Ying‐Hao Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ding, Jian, Xia Zhang, Xiaowu Huang, et al.. (2025). 304P: Prognostic markers and molecular insights: Navigating SCLC with liver metastasis. Journal of Thoracic Oncology. 20(3). S186–S186.

Tian, He, Ziyi Wang, Xiaodong Zhu, et al.. (2025). The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy. Biomarker Research. 13(1). 10–10. 4 indexed citations

Zheng, Yi-Min, Chao Gao, Wenxin Xu, et al.. (2025). The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC. Hepatology. 83(4). 771–788.

Xu, Wenxin, Jun Cao, Pei Wang, et al.. (2024). Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma. International Journal of Biological Sciences. 20(9). 3269–3284. 3 indexed citations

Sun, Hui‐Chuan, Xiao‐Dong Zhu, Ziyi Wang, et al.. (2024). Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis. SHILAP Revista de lepidopterología. 3(1). e000578–e000578. 1 indexed citations

Xu, Bin, Ziyi Wang, He Tian, et al.. (2024). Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy. Liver Cancer. 14(2). 1–16. 1 indexed citations

Sun, Hui‐Chuan, Ying‐Hao Shen, Xiao‐Dong Zhu, et al.. (2023). The development and prospects of liver surgery. SHILAP Revista de lepidopterología. 2(1). 100009–100009.

Weng, Jialei, Shaoqing Liu, Qiang Zhou, et al.. (2023). Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 11(6). e006655–e006655. 32 indexed citations

Guo, Xiaojun, Xiaoyong Huang, Xuan Yang, et al.. (2023). Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis. Cell Death and Disease. 14(2). 79–79. 14 indexed citations

10.

Xu, Minghao, Cheng Huang, Xiao‐Dong Zhu, et al.. (2023). Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study. Cancer Medicine. 12(8). 9202–9212. 8 indexed citations

11.

Zhou, Chenhao, Jialei Weng, Chunxiao Liu, et al.. (2023). Disruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma. Gastroenterology. 164(7). 1261–1278. 76 indexed citations

12.

Xu, Minghao, Bin Xu, Chenhao Zhou, et al.. (2022). An mALBI-Child–Pugh-based nomogram for predicting post-hepatectomy liver failure grade B–C in patients with huge hepatocellular carcinoma: a multi-institutional study. World Journal of Surgical Oncology. 20(1). 206–206. 5 indexed citations

13.

Xiao, Nan, Xiao‐Long Li, Xiao‐Dong Zhu, et al.. (2021). Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. Surgical Innovation. 29(2). 145–153.

14.

Hu, Jinwu, Guangyu Ding, Pei‐Yao Fu, et al.. (2020). Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. BioMed Research International. 2020(1). 6784138–6784138. 15 indexed citations

15.

Li, Xiao‐Long, Xiao‐Dong Zhu, Xuefeng Liu, et al.. (2020). A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. Surgery. 167(6). 926–932. 8 indexed citations

16.

Zhou, Qiang, Hao Cai, Minghao Xu, et al.. (2020). Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. Hepatobiliary & pancreatic diseases international. 20(1). 13–20. 11 indexed citations

17.

Shen, Ying‐Hao & Hui‐Chuan Sun. (2019). Assessment of liver reserve function before hepatectomy. 8(6). 469–472. 1 indexed citations

18.

Shen, Ying‐Hao, et al.. (2014). A Multimodal Approach to Developing EFL Listeners' Metacognition in a Multimedia Environment. ResearchSpace (University of Auckland). 1 indexed citations

19.

Shen, Ying‐Hao, Junfeng Zhang, Jing Zhou, et al.. (2013). Influences of gender, age, and body mass index on the arterial stiffness in hypertensive patients. 15(4). 465–468. 1 indexed citations

20.

Ding, Zhen‐Bin, Bo Hui, Ying‐Hong Shi, et al.. (2011). Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation. Clinical Cancer Research. 17(19). 6229–6238. 155 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact